… filed against a key patent for its ADAR-mediated RNA editing platform Axiomer™. The opposition was filed in … intellectual property estate surrounding its Axiomer RNA editing platform and the current generation of its … cell…”, which protects ProQR’s proprietary ADAR mediated RNA editing platform Axiomer. “This decision further supports …
… Officer role, with leadership oversight of Axiomer ® RNA-editing platform technology John Maraganore, PhD, former … provide strategic oversight of ProQR’s proprietary Axiomer RNA-editing platform technology. He is the scientific … including further building out the Company’s Axiomer RNA-editing technology as a value-generating platform. Smital …
… 10 (LCA10). Presentation title : Proof-of-concept for RNA-editing oligonucleotide QR-110 for treatment of inherited … clinical studies Poster presentation on Axiomer ® RNA editing technology A presentation will be delivered by … computational analytics of ProQR on the Axiomer ® RNA editing technology. Poster title: Structure-based …
… with LCA10 and preclinical data for ProQR’s Axiomer ® RNA-editing technology. Abstract titles: ○ Proof-of-concept for RNA-editing oligonucleotide QR-110 for treatment of inherited … ® EONs are designed to recruit an endogenously expressed RNA editing system called ADAR, which it can direct to the …
… (SAB). In vivo proof of concept data for novel Axiomer ® RNA editing platform technology presented at the OTS meeting … of concept data for its novel and proprietary Axiomer ® RNA editing technology platform at the Oligonucleotide …
… of RNA-based therapeutics, particularly in the area of RNA editing. As an expert in the field of ADAR and A-to-I … in advancing the company’s novel and proprietary Axiomer ® RNA editing technology. The board now consists of seven …
… ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across multiple therapeutic areas … Officer role, with leadership oversight of the Axiomer RNA-editing platform technology. John Maraganore, PhD, former …
… QR-313 was granted ODD in the U.S. and Europe. Axiomer ® RNA-editing technology was introduced at the Company’s second … QR-313 ready for clinical trials and validating our novel RNA-editing technology, Axiomer ® ,” said Daniel A. de Boer, … to future milestones and royalties. Axiomer ® RNA editing technology platform In June, ProQR introduced its …
… November 20 at 1:20-2:00 p.m. GMT Presentation at the 1 st RNA Editing Summit During the 1 st RNA Editing Summit to be held on November 19-20, 2019 in … and Development of ProQR. Presentation Title: Translating RNA Editing to Our Clinical Development Pipelines …
… advisory board. "Dr. Yu is a pioneer of targeted RNA editing to correct protein translation defects caused by … of therapies for rare genetic diseases based on novel RNA editing technologies including our Axiomer ® technology." … focuses on understanding the role of post-transcriptional RNA editing in regulating cellular processes, such as …